Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.…
Fortress Biotech (FBIO) Q3 2026 Earnings Call Transcript
Journey Medical (NASDAQ: DERM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 58 employees.
The shares were at 3.300 USD on 20 November 2026, down 63.1% over 52 weeks. Its 52-week range is 3.210 USD to 9.555 USD: the price is 65.5% below the high and 2.8% above the low.
Its market capitalisation is 93.16M USD.
Journey Medical reports return on equity of -35.9%, an operating margin of -2.9% and revenue up 7.6% year over year.
Its debt exceeds its cash by 3.30M USD, a debt-to-equity ratio of 0.80. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 12.75 USD is 286.4% above the current price. The next earnings report is expected on 24 March 2027.